APIs are no longer just a technical requirement; they have become strategic assets that drive business growth, elevate customer experiences and foster innovation. Traditional one-size-fits-all API ...

Biocon refuted media reports that said the company is evaluating a plan to sell its generic active pharmaceutical ingredient (API) business. (Image Credits: Pixabay) Biocon on Friday refuted media ...

“When I worked at Cambrex, I learned that generics are kind of boring,” says Kenneth Drew, senior director of North American sales and business development at Flamma, an Italian manufacturer of active ...

Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...

Foreign API makers unaccustomed to hosting FDA visitors may soon have to get their houses in order. A deal through which generics makers would pay $299 million in annual user fees to the FDA could ...

Italy is the world's second largest producer of active pharmaceutical ingredients (APIs), trailing only China. It holds nearly a 30% share in the U.S., still the largest market for branded and generic ...

Data APIs are rapidly becoming a favored conduit for frontend systems — websites, applications, and mobile apps, but also connected objects — to gain access to data served by their backend systems.

According to news report, Biocon is considering selling its generic active pharmaceutical ingredient (API) business, which is valued at approximately $1.5 billion, in order to lower its total debt.

SAN DIEGO--(BUSINESS WIRE)--ATX Networks, a global leader in broadband access and media distribution solutions, recently upgraded the Visium™ Set-Back Box (SBB), the company’s pocket-sized security ...